EVFM RSI Chart
Last 90 days
-66.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 16.0M | 0 | 0 | 0 |
2023 | 18.4M | 14.8M | 13.6M | 18.2M |
2022 | 11.4M | 15.6M | 20.2M | 16.8M |
2021 | 2.4M | 4.3M | 6.3M | 8.2M |
2020 | 0 | 0 | 0 | 446.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Dec 31, 2022 | pelletier saundra l | back to issuer | - | - | -50,000 | chief executive officer |
Dec 31, 2022 | file justin j. | back to issuer | - | - | -30,000 | chief financial officer |
May 27, 2022 | pelletier saundra l | bought | 49,702 | 0.3525 | 141,000 | chief executive officer |
Feb 18, 2022 | pelletier saundra l | acquired | - | - | 750,000 | chief executive officer |
Feb 18, 2022 | fitzpatrick alexander a | acquired | - | - | 300,000 | general counsel and secretary |
Feb 18, 2022 | file justin j. | acquired | - | - | 450,000 | chief financial officer |
Dec 31, 2021 | fitzpatrick alexander a | back to issuer | - | - | -120,000 | general counsel and secretary |
Dec 31, 2021 | pelletier saundra l | back to issuer | - | - | -300,000 | chief executive officer |
Dec 31, 2021 | file justin j. | back to issuer | - | - | -120,000 | chief financial officer |
Dec 20, 2021 | fitzpatrick alexander a | bought | 9,725 | 0.389 | 25,000 | general counsel and secretary |
Unveiling Evofem Biosciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Evofem Biosciences Inc News
Income Statement (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 |
Revenue | -25.5% | 3,603,000 | 4,839,000 | 5,112,000 | 2,458,000 | 5,809,000 | 181,000 | 6,371,000 | 6,034,000 | 4,251,000 | 3,570,000 | 1,712,000 | 1,857,000 | 1,105,000 | 691,500 | 278,000 |
Costs and Expenses | -21.6% | 6,447,000 | 8,219,000 | 8,664,000 | 9,794,000 | 9,388,000 | 12,233,000 | 25,095,000 | 30,453,000 | 33,180,000 | 40,988,000 | 45,081,000 | 42,999,000 | 45,977,000 | - | - |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 45,081,000 | 42,999,000 | 45,977,000 | 36,019,500 | 26,434,000 |
S&GA Expenses | -10.8% | 2,345,000 | 2,628,000 | 2,985,000 | 2,197,000 | 3,854,000 | 7,000,000 | 11,948,000 | 12,298,000 | 12,705,000 | 24,922,000 | 30,468,000 | 27,237,000 | 30,525,000 | 23,914,500 | 14,700,000 |
R&D Expenses | -57.0% | 594,000 | 1,383,000 | 614,000 | 402,000 | 540,000 | 1,690,000 | 5,207,000 | 7,744,000 | 10,391,000 | 8,659,000 | 8,701,000 | 8,507,000 | 7,262,000 | 5,946,000 | 4,217,000 |
EBITDA Margin | 8.9% | 3.44 | 3.16 | 3.92 | 5.08 | -2.38 | -4.35 | -5.76 | -18.00 | -16.47 | -24.42 | -30.04 | -33.41 | -68.89 | - | - |
Interest Expenses | 144.6% | 564,000 | -1,263,500 | 2,400,000 | 2,400,000 | 565,000 | 362,000 | 800,000 | 700,000 | 523,000 | 313,000 | 700,000 | 700,000 | 1,152,000 | 1,700,000 | 700,000 |
Income Taxes | - | - | - | 11,000 | 3,000 | 3,000 | 8,000 | 13,000 | 20,000 | 3,000 | 6,000 | - | 12,000 | -1,000 | 2,000 | 2,000 |
Earnings Before Taxes | -127.5% | -4,809,000 | -2,114,000 | 66,016,000 | -8,555,000 | -2,351,000 | -8,328,000 | 89,519,000 | -125,960,000 | -31,885,000 | -51,548,000 | -74,061,000 | -33,414,000 | -46,152,000 | -40,596,000 | -29,897,000 |
EBT Margin | 8.5% | 3.16 | 2.91 | 3.45 | 4.74 | -2.56 | -4.55 | -5.93 | -18.21 | -16.76 | -24.89 | -30.86 | -34.54 | -70.68 | - | - |
Net Income | -127.5% | -4,809,000 | -2,114,000 | 66,005,000 | -8,558,000 | -2,354,000 | -8,336,000 | 89,506,000 | -125,980,000 | -31,888,000 | -51,554,000 | -74,061,000 | -33,426,000 | -46,151,000 | -40,598,000 | -29,899,000 |
Net Income Margin | 8.5% | 3.16 | 2.91 | 3.45 | 4.74 | -2.56 | -4.56 | -5.93 | -18.21 | -16.76 | -24.89 | -30.86 | -34.54 | -70.68 | - | - |
Free Cashflow | 164.1% | 109,000 | -170,000 | -2,364,000 | -1,495,000 | -4,943,000 | -6,566,000 | -16,370,000 | -26,830,000 | -20,985,000 | -21,318,000 | -37,964,000 | -54,910,000 | -35,414,000 | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -22.1% | 8.00 | 11.00 | 13.00 | 14.00 | 26.00 | 25.00 | 42.00 | 53.00 | 35.00 | 43.00 | 67.00 | 109 | 93.00 | 110 | 112 | 135 | 16.00 | 28.00 | 39.00 | 54.00 | 3.00 |
Current Assets | -24.8% | 7.00 | 9.00 | 12.00 | 12.00 | 17.00 | 13.00 | 32.00 | 42.00 | 21.00 | 30.00 | 55.00 | 96.00 | 80.00 | 98.00 | 102 | 128 | 14.00 | 26.00 | 38.00 | 53.00 | 1.00 |
Cash Equivalents | 18.8% | 1.00 | 1.00 | - | - | 1.00 | 3.00 | 8.00 | 20.00 | 3.00 | 14.00 | 15.00 | 47.00 | 45.00 | 72.00 | 87.00 | 124 | 9.00 | 17.00 | 32.00 | 51.00 | 0.00 |
Inventory | -23.0% | 1.00 | 2.00 | 3.00 | 4.00 | 5.00 | 5.00 | - | - | - | 8.00 | 10.00 | 11.00 | 9.00 | 7.00 | 3.00 | 1.00 | - | - | - | - | - |
Net PPE | -0.2% | 1.00 | 1.00 | 2.00 | 2.00 | 4.00 | 4.00 | 4.00 | 5.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 0.00 | 1.00 | 0.00 | 1.00 |
Liabilities | 2.4% | 74.00 | 72.00 | 68.00 | 70.00 | 82.00 | 97.00 | 120 | 269 | 159 | 142 | 126 | 100 | 107 | 109 | 72.00 | 67.00 | 15.00 | 13.00 | 15.00 | 19.00 | 32.00 |
Current Liabilities | 2.5% | 74.00 | 72.00 | 68.00 | 70.00 | 80.00 | 94.00 | 117 | 266 | 154 | 138 | 95.00 | 68.00 | 76.00 | 77.00 | 66.00 | 62.00 | 14.00 | 13.00 | 15.00 | 19.00 | 32.00 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | 27.00 | 26.00 | 26.00 | 25.00 | - | - | - | - | - | - | - |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | 27.00 | 26.00 | 26.00 | 25.00 | - | - | - | - | - | - | - |
Shareholder's Equity | -6.2% | -70.67 | -66.51 | - | - | -56.40 | -71.80 | - | - | - | -104 | - | 9.00 | - | 1.00 | 40.00 | 69.00 | 1.00 | 16.00 | 24.00 | 36.00 | - |
Retained Earnings | -0.6% | -893 | -888 | -884 | -949 | -941 | -938 | -930 | -1,000 | -892 | -860 | -809 | -735 | -701 | -655 | -614 | -585 | -532 | -513 | -500 | -486 | -451 |
Additional Paid-In Capital | 0.0% | 823 | 823 | 829 | 821 | 820 | 817 | 815 | 802 | 759 | 751 | 745 | 744 | 688 | 657 | 655 | 654 | 533 | 529 | 525 | 522 | 422 |
Shares Outstanding | 129.6% | 46.00 | 20.00 | 6.00 | 3.00 | - | 121 | 102 | - | 12.00 | - | 8.00 | 7.00 | 5.00 | 5.00 | - | - | - | - | - | - | - |
Float | - | - | - | - | 2.00 | - | - | - | 89.00 | - | - | - | 173 | - | - | - | 191 | - | - | - | 43.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 172.4% | 123 | -170 | -2,364 | -1,494 | -4,940 | -6,531 | -16,300 | -26,660 | -20,919 | -21,265 | -37,367 | -53,577 | -34,458 | -39,079 | -35,822 | -15,052 | -14,876 | -13,446 | -14,425 | -19,548 | -7,678 |
Share Based Compensation | -3.7% | 237 | 246 | 258 | 268 | 417 | 183 | 982 | 1,081 | 1,067 | 1,350 | 1,091 | 2,993 | 3,464 | 1,625 | 1,637 | 6,034 | 3,401 | 1,839 | 2,263 | 2,515 | 1,962 |
Cashflow From Investing | -Infinity% | -14.00 | - | - | -1.00 | -3.00 | -35.00 | -70.00 | -170 | -66.00 | -53.00 | -597 | -1,333 | -706 | -1,421 | -297 | 1,045 | 6,902 | -4,627 | -3,738 | - | 250 |
Cashflow From Financing | -100.0% | - | 340 | 2,138 | 597 | 1,701 | 1,500 | 3,946 | 41,364 | 15,129 | 9,866 | 16.00 | 52,805 | 28,006 | 24,917 | -603 | 128,548 | 1,364 | 2,192 | -411 | 70,028 | 6,267 |
Buy Backs | - | - | - | - | - | - | - | - | 18.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Product sales, net | $ 3,603 | $ 5,809 |
Operating Expenses: | ||
Cost of goods sold | 684 | 1,376 |
Research and development | 594 | 540 |
Selling and marketing | 2,345 | 3,854 |
General and administrative | 2,824 | 3,618 |
Total operating expenses | 6,447 | 9,388 |
Loss from operations | (2,844) | (3,579) |
Other income (expense): | ||
Interest income | 4 | 18 |
Other expense, net | (616) | (318) |
Loss on issuance of financial instruments (Note 8) | (3,275) | (84) |
Gain on debt extinguishment | 1,120 | |
Change in fair value of financial instruments (Note 6) | 802 | 1,612 |
Total other income (expense), net | (1,965) | 1,228 |
Loss before income tax | (4,809) | (2,351) |
Income tax expense | (3) | |
Net loss | (4,809) | (2,354) |
Convertible preferred stock deemed dividends | (47) | |
Net loss attributable to common stockholders | $ (4,856) | $ (2,354) |
Net loss per share attributable to common stockholders | ||
Earnings per share - basic | $ (0.16) | $ (1.85) |
Earnings per share - diluted | $ (0.16) | $ (1.85) |
Weighted-average shares used to compute net | ||
loss per share attributable to common shareholders - basic | 31,194,393 | 1,271,524 |
loss per share attributable to common shareholders - diluted | 31,194,393 | 1,271,524 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | ||
Restricted cash | 689 | 580 |
Trade accounts receivable, net | 4,306 | 5,738 |
Inventories | 1,306 | 1,697 |
Prepaid and other current assets | 622 | 1,195 |
Total current assets | 6,923 | 9,210 |
Property and equipment, net | 1,200 | 1,203 |
Operating lease right-of-use assets | 59 | 106 |
Other noncurrent assets | 35 | 35 |
Total assets | 8,217 | 10,554 |
Current liabilities: | ||
Accounts payable | 16,294 | 17,020 |
Accrued expenses | 4,575 | 4,227 |
Accrued compensation | 3,261 | 2,609 |
Operating lease liabilities-current | 55 | 97 |
Derivative liabilities | 4,310 | 1,926 |
Other current liabilities | 3,391 | 3,316 |
Total current liabilities | 74,239 | 72,463 |
Operating lease liabilities- noncurrent | 4 | 8 |
Total liabilities | 74,243 | 72,471 |
Commitments and contingencies (Note 7) | ||
Convertible and redeemable preferred stock, $0.0001 par value, Senior to common stock | ||
Series E-1, and F-1 convertible preferred stock, 2,300 and 95,000 shares authorized; 1,921 and 1,874 shares of E-1 issued and outstanding at March 31, 2024 and December 31, 2023, respectively; 22,280 shares of F-1 issued and outstanding at each of March 31, 2024 and December 31, 2023 | 4,640 | 4,593 |
Stockholders’ deficit: | ||
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | ||
Common Stock, $0.0001 par value; 3,000,000,000 shares authorized; 48,710,395 and 20,007,799 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 5 | 2 |
Additional paid-in capital | 823,409 | 823,036 |
Accumulated other comprehensive loss | (525) | (849) |
Accumulated deficit | (893,555) | (888,699) |
Total stockholders’ deficit | (70,666) | (66,510) |
Total liabilities, convertible and redeemable preferred stock and stockholders’ deficit | 8,217 | 10,554 |
Baker Bros. Notes [Member] | ||
Current liabilities: | ||
Convertible notes | 13,252 | 14,731 |
Adjuvant Notes [Member] | ||
Current liabilities: | ||
Convertible notes | $ 29,101 | $ 28,537 |